Copyright
©The Author(s) 2023.
World J Clin Cases. Jan 16, 2023; 11(2): 268-291
Published online Jan 16, 2023. doi: 10.12998/wjcc.v11.i2.268
Published online Jan 16, 2023. doi: 10.12998/wjcc.v11.i2.268
Factors | Brief description | Ref. |
Disease type | The relapse rate is highest in ALL patients, followed by AML patients and CML patients | [161] |
Pretransplant disease status | The risk of relapse is significantly higher in nonremission patients and patients with a high level of residual leukemia cells before transplantation | [151] |
Risk stratification | The level of risk is positively correlated with the relapse rate and negatively correlated with the disease-free survival rate | [162] |
Stem cell source | Peripheral blood stem cells contain more lymphocytes with a more potent GVL effect; as a result, the relapse rate of BMT is higher than that of PBSCT | [163,164] |
Preconditioning | Myeloablative preconditioning is more effective in reducing post-transplant relapse than reduced intensity conditioning and nonmyeloablative preconditioning; T cell depletion is associated with increased relapse rates in CML and AML | [164,165] |
GVHD | Post-transplant GVHD, especially cGVHD, is associated with a significantly lower relapse rate and a higher survival rate | [166,167] |
- Citation: Chen YF, Li J, Xu LL, Găman MA, Zou ZY. Allogeneic stem cell transplantation in the treatment of acute myeloid leukemia: An overview of obstacles and opportunities. World J Clin Cases 2023; 11(2): 268-291
- URL: https://www.wjgnet.com/2307-8960/full/v11/i2/268.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i2.268